JP2024535851A5 - - Google Patents

Info

Publication number
JP2024535851A5
JP2024535851A5 JP2024516855A JP2024516855A JP2024535851A5 JP 2024535851 A5 JP2024535851 A5 JP 2024535851A5 JP 2024516855 A JP2024516855 A JP 2024516855A JP 2024516855 A JP2024516855 A JP 2024516855A JP 2024535851 A5 JP2024535851 A5 JP 2024535851A5
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
seq
cdr1
cdr2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024516855A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024535851A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2022/119334 external-priority patent/WO2023041041A1/en
Publication of JP2024535851A publication Critical patent/JP2024535851A/ja
Publication of JP2024535851A5 publication Critical patent/JP2024535851A5/ja
Pending legal-status Critical Current

Links

JP2024516855A 2021-09-17 2022-09-16 D3結合分子及びその使用 Pending JP2024535851A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2021/119011 2021-09-17
CN2021119011 2021-09-17
PCT/CN2022/119334 WO2023041041A1 (en) 2021-09-17 2022-09-16 D3-binding molecules and uses thereof

Publications (2)

Publication Number Publication Date
JP2024535851A JP2024535851A (ja) 2024-10-02
JP2024535851A5 true JP2024535851A5 (cg-RX-API-DMAC7.html) 2025-10-01

Family

ID=85602107

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024516855A Pending JP2024535851A (ja) 2021-09-17 2022-09-16 D3結合分子及びその使用

Country Status (16)

Country Link
US (1) US20240376194A1 (cg-RX-API-DMAC7.html)
EP (1) EP4401775A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024535851A (cg-RX-API-DMAC7.html)
KR (1) KR20240055852A (cg-RX-API-DMAC7.html)
CN (2) CN118234510A (cg-RX-API-DMAC7.html)
AU (1) AU2022345323A1 (cg-RX-API-DMAC7.html)
CA (1) CA3231586A1 (cg-RX-API-DMAC7.html)
CL (2) CL2024000785A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024003144A2 (cg-RX-API-DMAC7.html)
CR (1) CR20240135A (cg-RX-API-DMAC7.html)
DO (2) DOP2024000052A (cg-RX-API-DMAC7.html)
EC (1) ECSP24021498A (cg-RX-API-DMAC7.html)
IL (1) IL311510A (cg-RX-API-DMAC7.html)
MX (1) MX2024003331A (cg-RX-API-DMAC7.html)
PE (1) PE20241133A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023041041A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121494919A (zh) * 2024-12-16 2026-02-10 渤海大学 一种海参卵源肽复合物及其在抗氧化和降低黑色素上的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2530091T3 (pl) * 2010-01-29 2018-08-31 Chugai Seiyaku Kabushiki Kaisha Przeciwciało przeciwko dll3
GB201302447D0 (en) * 2013-02-12 2013-03-27 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
CA2922544A1 (en) * 2013-08-28 2015-03-05 Stemcentrx, Inc. Engineered anti-dll3 conjugates and methods of use
EP3107576A4 (en) * 2014-02-21 2017-09-06 Abbvie Stemcentrx LLC Anti-dll3 antibodies and drug conjugates for use in melanoma
TWI793062B (zh) * 2015-07-31 2023-02-21 德商安美基研究(慕尼黑)公司 Dll3及cd3抗體構築體
EP3337517A4 (en) * 2015-08-20 2019-04-17 Abbvie Stemcentrx LLC ANTI-DLL3 ANTIBODY AGGREGATE CONJUGATES AND METHOD OF USE
US20190225685A1 (en) * 2018-01-24 2019-07-25 Abbvie Stemcentrx Llc Anti-dll3 antibody drug conjugates and methods of use
AU2019267349B2 (en) * 2018-05-08 2025-06-05 Phanes Therapeutics, Inc. Anti-DLL3 antibodies and uses thereof
CN119306844A (zh) * 2018-09-25 2025-01-14 哈普恩治疗公司 Dll3结合蛋白及使用方法
JP7611820B2 (ja) * 2018-10-11 2025-01-10 インヒブルクス バイオサイエンシズ インコーポレイテッド Dll3シングルドメイン抗体およびその治療用組成物

Similar Documents

Publication Publication Date Title
JP7840836B2 (ja) 改善された血清アルブミン結合性免疫グロブリン可変ドメイン
JP6728053B2 (ja) 抗mcam抗体及び関連する使用方法
CN110669135B (zh) 一种双特异性抗体及其用途
TW201837174A (zh) 抗gprc5d抗體及包含該抗體之分子
JP2018532401A (ja) 新規抗‐メソテリン抗体およびそれを含む組成物
KR20160131061A (ko) 항-mcam 항체 및 관련된 사용 방법
JP7458567B2 (ja) C-met結合剤
JP2021512159A5 (cg-RX-API-DMAC7.html)
JP2021534735A (ja) ヒトTim−3に対するモノクローナル抗体
KR102500845B1 (ko) 항-tigit 항체 및 이의 용도
US20230357398A1 (en) Novel human antibodies binding to human cd3 epsilon
WO2024113099A1 (en) Protease cleavable recombinant bispecific antibodies and compositions and uses thereof
JP2023504733A (ja) 抗clec-1a抗体及びその抗原結合性断片
JP2021501583A (ja) 抗体および使用方法
TW202330596A (zh) 經修飾的蛋白或多肽
WO2022126416A1 (zh) 抗bcma抗体及其制备方法和应用
CN108290942A (zh) 与人及小鼠信号素3a交联的抗体及其用途
KR20230162597A (ko) 안정적인 다중 특이성 분자 및 그 이용
CN116333127B (zh) 靶向人lilrb2的纳米抗体及其应用
EP4393946A1 (en) Cdc platform antibody
US20260022165A1 (en) Antibodies targeting cell surface deposited complement protein c3d and use thereof
US20240425575A1 (en) Anti-ang2 antibody, preparation method therefor, and application thereof
JP2024533485A (ja) がんの治療のためのDR5標的化Multabody
WO2024130395A1 (en) Multivalent hematopoietic cell engagers or activators
TW202544031A (zh) 抗tigit/抗pd-l1雙特異性抗體及其用途